On the risk of delisting of ordinary shares of Olema Pharmaceuticals, Inc. (OLMA)

The International Trading System Limited (hereinafter — ITS) informs on the information concerning delisting risk of ordinary shares of Olema Pharmaceuticals, Inc. (ISIN US68062P1066, Shares) from The Nasdaq Stock Market LLC (Nasdaq).

Information on delisting risk of ordinary shares by Nasdaq

On March 18, 2025, Olema Pharmaceuticals, Inc. (the Company) submitted Annual report on Form 10-K to The United States Securities and Exchange Commission. According to the report, the Company has incurred net losses since inception and expects to continue to incur net losses for the foreseeable future, has not generated any revenue from product sales to date and has financed its operations principally through sales of shares of common stock. These conditions led the Company’s management to raise substantial doubt about its ability to continue as a going concern for more than twelve months from the date of these financial statements. For more information, please refer to the report available on the SEC website.

Previously, similar statements were made in the Company’s Quarterly reports on Form 10-Q.

Information regarding possible actions to be taken by ITS

If Nasdaq suspends trading in the Company’s ordinary shares, ITS will prohibit submission of orders and will restrict ability to conclude agreements in respect of the Company’s ordinary shares. If the Company’s ordinary shares are delisted from Nasdaq, ITS will terminate trading in the Company’s ordinary shares. However, in case the Company’s ordinary shares become listed, or admitted to trading on another Recognised Trading Venue, ITS will consider but does not guarantee continuation of trading in the Company’s ordinary shares.